Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("DORR, F. A")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 25

  • Page / 1
Export

Selection :

  • and

Prognostic factors observed in current clinical trialsDORR, F. A.Cancer. 1993, Vol 71, Num 6, pp 2163-2168, issn 0008-543X, SUPConference Paper

A phase I evaluation of multitargeted antifolate (MTA, Ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationRINALDI, D. A; KUHN, J. G; MASCORRO, D et al.Cancer chemotherapy and pharmacology. 1999, Vol 44, Num 5, pp 372-380, issn 0344-5704Article

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancerCOPLEY-MERRIMAN, C; CORRAL, J; KING, K et al.Lung cancer. 1996, Vol 14, Num 1, pp 45-61, issn 0169-5002Article

Locally advanced breast cancer current status and future directionsDORR, F. A; BADER, J; FRIEDMAN, M. A et al.International journal of radiation oncology, biology, physics. 1989, Vol 16, Num 3, pp 775-784, issn 0360-3016, 10 p.Article

Opportunities in clinical trials : adjuvant breast cancerFRIEDMAN, M. A; DORR, F. A.Cancer. 1990, Vol 66, Num 6, pp 1412-1415, issn 0008-543X, 4 p., SupplConference Paper

Phase I clinical and phramacokinetic investigation of didemnin B, a cyclic depsipeptideDORR, F. A; KUHN, J. G; PHILLIPS, J et al.European journal of cancer & clinical oncology. 1988, Vol 24, Num 11, pp 1699-1706, issn 0277-5379Article

Presence of an estrogen-regulated protein in endometrial cancerSLEDGE, G. W. JR; RAMZY, I; DRESSLER, L. G et al.Obstetrics and gynecology (New York. 1953). 1985, Vol 66, Num 3, pp 423-427, issn 0029-7844Article

New anticancer drugsKISNER, D. L; KUHN, J. G; WEISS, G. R et al.Cancer chemotherapy. 1983, Num 5, pp 120-160Article

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's diseaseYACYSHYN, B. R; BARISH, C; GOFF, J et al.Alimentary pharmacology & therapeutics. 2002, Vol 16, Num 10, pp 1761-1770, issn 0269-2813, 10 p.Article

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancerMCPHILLIPS, F; MULLEN, P; MONIA, B. P et al.British journal of cancer. 2001, Vol 85, Num 11, pp 1753-1758, issn 0007-0920Article

Prognostic factors in stage D2 prostate cancer ; important implications for future trials : results of a cooperative intergroup study (INT.0036)EISENBERGER, M. A; CRAWFORD, E. D; WOLF, M et al.Seminars in oncology. 1994, Vol 21, Num 5, pp 613-619, issn 0093-7754Article

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)STEVENSON, J. P; YAO, K.-S; DORR, F. A et al.Journal of clinical oncology. 1999, Vol 17, Num 7, pp 2227-2236, issn 0732-183XArticle

c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)O'DWYER, P. J; STEVENSON, J. P; GALLAGHER, M et al.Clinical cancer research. 1999, Vol 5, Num 12, pp 3977-3982, issn 1078-0432Article

Antisense oligonucleotides to protein kinase C-α and C-raf kinase : Rationale and clinical experience in patients with solid tumorsDORR, F. A; KISNER, D. L.Handbook of experimental pharmacology. 1997, Vol 131, pp 463-476, issn 0171-2004Article

Improvements in survival and Clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : A randomized trialBURRIS, H. A; MOORE, M. J; NELSON, R et al.Journal of clinical oncology. 1997, Vol 15, Num 6, pp 2403-2413, issn 0732-183XArticle

Metastatic bladder cancer : advances in treatmentSTADLER, W. M; KUZEL, T. M; RAGHAVAN, D et al.European journal of cancer (1990). 1997, Vol 33, pp S23-S26, issn 0959-8049, SUP1Article

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patientsO'SHAUGHNESSY, J. A; DENICOFF, A. M; DORR, F. A et al.Annals of oncology. 1994, Vol 5, Num 8, pp 709-716, issn 0923-7534Article

Leuprolide with and without flutamide in advanced prostate cancerCRAWFORD, E. D; BLUMENSTEIN, B. A; GOODMAN, P. J et al.Cancer. 1990, Vol 66, Num 5, pp 1039-1044, issn 0008-543X, 6 p.Conference Paper

Tamoxifen and fenretinide in women with metastatic breast cancerZUJEWSKI, J; PAI, L; GOSSARD, M et al.Breast cancer research and treatment. 1999, Vol 57, Num 3, pp 277-283, issn 0167-6806Article

Phase II study of single-agent Gemcitabine in previously untreated patients with metastatic urothelial cancerSTADLER, W. M; KUZEL, T; ROTH, B et al.Journal of clinical oncology. 1997, Vol 15, Num 11, pp 3394-3398, issn 0732-183XArticle

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalationRINALDI, D. A; BURRIS, H. A; CLARK, G et al.Journal of clinical oncology. 1995, Vol 13, Num 11, pp 2842-2850, issn 0732-183XArticle

National cancer institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placeboBENSON, R. C; CRAWFORD, E. D; EISENBERGER, M. A et al.Seminars in oncology. 1991, Vol 18, Num 5, pp 9-12, issn 0093-7754, SUP6Conference Paper

A controlled trial of leuprolide with and without flutamide in prostatic carcinomaCRAWFORD, E. D; EISENBERGER, M. A; MCLOUD, D. G et al.The New England journal of medicine. 1989, Vol 321, Num 7, pp 419-424, issn 0028-4793Article

Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibioticDORR, F. A; VON HOFF, D. D; KUHN, J. G et al.Cancer research (Baltimore). 1986, Vol 46, Num 5, pp 2562-2565, issn 0008-5472Article

Miscellaneous anticancer drugsKISNER, D. L; KUHN, J. G; WEISS, G. R et al.Cancer chemotherapy. 1983, Num 5, pp 161-170Article

  • Page / 1